Baird Downgrades Maxar Technologies to Neutral, Raises Price Target to $53

Baird analyst Peter Arment downgrades Maxar Technologies (NYSE:MAXR) from Outperform to Neutral and raises the price target from $45 to $53.

byBenzinga Newsdesk

December 19, 2022

1 minute read

Baird analyst Peter Arment downgrades Maxar Technologies (NYSE:MAXR) from Outperform to Neutral and raises the price target from $45 to $53.

Qiagen Stock Gains As Non COVID Sales Boosts Q2 Topline, Bottom-line

By Vandana Singh

Today, 9:19 PM

Qiagen N.V. (NYSE:QGEN) reported after the close of the market Thursday that its second-quarter revenues jumped 28% Y/Y as growth in…

QGEN

$1000 Invested In Zoetis 5 Years Ago Would Be Worth This Much Today

By Benzinga Insights

Today, 9:19 PM

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 13.96% on an annualized basis producing an average annual return of 23.78%. Currently, Zoetis has a market capitalization of $83.80 billion.

ZTS

Treace Medical Concepts Q3 EPS $(0.12), Inline, Sales $21.62M Beat $21.00M Estimate

By Benzinga Newsdesk

Today, 9:19 PM

Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. The company reported quarterly sales of $21.62 million which beat the analyst consensus

TMCI

FDA
News

Synlogic Presents Data On SYNB8802 For Enteric Hyperoxaluria At American Urological Association (AUA) Annual Meeting

By Benzinga Newsdesk

Today, 9:19 PM

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational Synthetic

SYBX

Baird Downgrades Maxar Technologies to Neutral, Raises Price Target to $53

Related Posts

Qiagen Stock Gains As Non COVID Sales Boosts Q2 Topline, Bottom-line

$1000 Invested In Zoetis 5 Years Ago Would Be Worth This Much Today

Treace Medical Concepts Q3 EPS $(0.12), Inline, Sales $21.62M Beat $21.00M Estimate

Synlogic Presents Data On SYNB8802 For Enteric Hyperoxaluria At American Urological Association (AUA) Annual Meeting